Schiff base forming sunscreen filters for long-wear UV protection

描述（由申请人提供）：根据美国癌症协会的说法，降低非黑色素瘤皮肤癌风险的最佳方法是通过使用广谱防晒霜来“实践防晒安全”。商业紫外线（UV）过滤剂的主要限制是它们缺乏与人类皮肤的亲和力，并且容易被水、汗水和正常穿戴去除。因此，消费者必须不断地重新涂抹防晒霜以获得充分的保护效果。产品和长期目标：Nanometics已经修改了TiO 2和ZnO颗粒，以开发长效紫外线防晒过滤器。新的紫外线过滤剂是由廉价的商业原料合成的，并将作为粉末在全球销售，作为各种皮肤病产品的长效成分。预计这些紫外线过滤剂将减少产品重复使用的需求。技术创新：天然存在的抗氧化剂配体被吸附到防晒级TiO 2或ZnO的表面上，并用作异双功能连接剂以将UV过滤剂共价键合到皮肤上。预计这些 新的紫外线过滤剂在输送到皮肤时将表现出增强的防水性，并提供长期的紫外线辐射防护。I期结局：第一阶段SBIR研究旨在证明改性TiO 2和ZnO颗粒作为长期磨损UV过滤剂的可行性，并降低成本密集型第二阶段SBIR研究的技术风险。初步的体外和体内研究已经证明，异双功能连接体的吸附不会对颗粒的光保护性质或安全性产生负面影响。第二阶段假设：（1）当在人类临床防晒因子测定中评价时，改性的TiO 2和ZnO颗粒将防水至少80分钟;（2）异双官能连接体的吸附不会增强颗粒的皮肤渗透特性;和（3）将开发商业规模量的改性颗粒的成本有效的方案。商业机会：到2018年，紫外线过滤器的全球市场规模预计将超过6.5亿美元。在成功完成本提案中的里程碑后，Nanometics将把PLP-颗粒作为新型无机紫外线过滤剂商业化，并作为皮肤病产品的成分在全球销售。

DESCRIPTION (provided by applicant): According to the American Cancer Society, the best way to lower the risk of non-melanoma skin cancer is "to practice sun safety" by applying broad-spectrum sunscreens. A major limitation of commercial Ultraviolet (UV) filters is that they lack affinity with human skin and are easily removed by water, perspiration, and normal wear. Consequently, the consumer must continually reapply sunscreen to gain full protective benefit. Product and Long-Term Goal: Nanometics has modified TiO2 and ZnO particles to develop long-wear UV sunscreen filters. The new UV filters are synthesized from inexpensive commercial starting materials and will be sold globally as powders for incorporation as long-wear ingredients in a variety of dermatological products. It is anticipated that these UV filters wll alleviate the need for constant product reapplication. Technical Innovation: A naturally occurring anti-oxidant ligand is adsorbed onto the surface of sunscreen grade TiO2 or ZnO and utilized as a heterobifunctional linker to covalently bond UV filters to the skin. It is anticipated that these new UV filters will exhibit enhanced water-resistance when delivered to the skin and provide long-wear protection from UV radiation. Phase I Outcomes: Phase I SBIR studies were designed to demonstrate the feasibility of modified TiO2 and ZnO particles as long-wear UV filters and de-risk the technology for the more cost-intensive Phase II SBIR studies. Preliminary in vitro and in vivo studies have demonstrated that adsorption of the heterobifunctional linker does not negatively influence the photo-protective properties or safety profile of the particles. Phase II Hypotheses: (1) Modified TiO2 and ZnO particles will be water-resistant for at least 80 minutes when evaluated in a human clinical sun protection factor assay; (2) adsorption of the heterobifunctional linker does not enhance the dermal penetration profile of the particles; and (3) a cost-effective protocol to commercial- scale quantities of modified particles will be developed. Commercial Opportunity: The global market size for UV filters is estimated to exceed $650 million by 2018. Contingent upon successful completion of the milestones in this proposal, Nanometics will commercialize PLP- Particles as novel inorganic UV filters to be sold globally as ingredients for dermatological products.